These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
165 related items for PubMed ID: 12820363
21. Plasma concentrations of tumour dimeric pyruvate kinase are increased in patients with chronic cardiac failure. McDowell G, Gupta S, Dellerba M, Coppinger T, Levy RD, Keevil BG. Ann Clin Biochem; 2004 Nov; 41(Pt 6):491-3. PubMed ID: 15588442 [Abstract] [Full Text] [Related]
22. Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation. Spoden GA, Mazurek S, Morandell D, Bacher N, Ausserlechner MJ, Jansen-Dürr P, Eigenbrodt E, Zwerschke W. Int J Cancer; 2008 Jul 15; 123(2):312-321. PubMed ID: 18425820 [Abstract] [Full Text] [Related]
23. Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy. Hardt PD, Ewald N. Expert Rev Mol Diagn; 2008 Sep 15; 8(5):579-85. PubMed ID: 18785806 [Abstract] [Full Text] [Related]
24. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures. Elia S, Massoud R, Guggino G, Cristino B, Cortese C, De Massimi AR, Zenobi R. Eur J Cardiothorac Surg; 2008 Apr 15; 33(4):723-7. PubMed ID: 18261916 [Abstract] [Full Text] [Related]
25. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker. Kumar Y, Tapuria N, Kirmani N, Davidson BR. Eur J Gastroenterol Hepatol; 2007 Mar 15; 19(3):265-76. PubMed ID: 17301655 [Abstract] [Full Text] [Related]
26. Molecular and cellular regulation of pyruvate kinase in red blood cells. Jacobasch G, Holzhütter H. Haematologia (Budap); 1984 Mar 15; 17(2):259-66. PubMed ID: 6534831 [Abstract] [Full Text] [Related]
27. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma. Oremek GM, Sapoutzis N, Kramer W, Bickeböller R, Jonas D. Anticancer Res; 2000 Mar 15; 20(6D):5095-8. PubMed ID: 11326675 [Abstract] [Full Text] [Related]
28. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, Kinoshita T, Saito N, Ochiai A, Tomita M, Esumi H, Soga T. Cancer Res; 2009 Jun 01; 69(11):4918-25. PubMed ID: 19458066 [Abstract] [Full Text] [Related]
29. Value of tumor M2-PK in thyroid carcinoma: a pilot study. Bena-Boupda NF, Rezai SS, Klett R, Eigenbrodt E, Bauer R. Anticancer Res; 2003 Jun 01; 23(6D):5237-40. PubMed ID: 14981996 [Abstract] [Full Text] [Related]
30. Pyruvate kinase activity in the placentas of women living in polluted and unpolluted environments. Kedryna T, Gumińska M, Lucyna Z. Med Sci Monit; 2004 Dec 01; 10(12):CR672-8. PubMed ID: 15567985 [Abstract] [Full Text] [Related]
31. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Schneider J, Schulze G. Anticancer Res; 2003 Dec 01; 23(6D):5089-93. PubMed ID: 14981971 [Abstract] [Full Text] [Related]
32. Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Steták A, Veress R, Ovádi J, Csermely P, Kéri G, Ullrich A. Cancer Res; 2007 Feb 15; 67(4):1602-8. PubMed ID: 17308100 [Abstract] [Full Text] [Related]
33. The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma. Weinberger R, Appel B, Stein A, Metz Y, Neheman A, Barak M. Eur J Cancer Care (Engl); 2007 Jul 15; 16(4):333-7. PubMed ID: 17587357 [Abstract] [Full Text] [Related]
34. Alterations in the glycolytic and glutaminolytic pathways after malignant transformation of rat liver oval cells. Mazurek S, Eigenbrodt E, Failing K, Steinberg P. J Cell Physiol; 1999 Oct 15; 181(1):136-46. PubMed ID: 10457361 [Abstract] [Full Text] [Related]
35. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis. Goonetilleke KS, Mason JM, Siriwardana P, King NK, France MW, Siriwardena AK. Pancreas; 2007 Apr 15; 34(3):318-24. PubMed ID: 17414054 [Abstract] [Full Text] [Related]
36. Different involvement for aldolase isoenzymes in kidney glucose metabolism: aldolase B but not aldolase A colocalizes and forms a complex with FBPase. Yañez AJ, Ludwig HC, Bertinat R, Spichiger C, Gatica R, Berlien G, Leon O, Brito M, Concha II, Slebe JC. J Cell Physiol; 2005 Mar 15; 202(3):743-53. PubMed ID: 15389646 [Abstract] [Full Text] [Related]
37. Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF. Schmidt M, Kammerer U, Segerer S, Cramer A, Kohrenhagen N, Dietl J, Voelker HU. Eur J Obstet Gynecol Reprod Biol; 2008 Jul 15; 139(1):72-8. PubMed ID: 18394773 [Abstract] [Full Text] [Related]
38. Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis. Kumar Y, Gurusamy K, Pamecha V, Davidson BR. Pancreas; 2007 Aug 15; 35(2):114-9. PubMed ID: 17632316 [Abstract] [Full Text] [Related]
39. In vivo factors influencing tumour M2-pyruvate kinase level in human pancreatic cancer cell lines. Kumar Y, Mazurek S, Yang S, Failing K, Winslet M, Fuller B, Davidson BR. Tumour Biol; 2010 Apr 15; 31(2):69-77. PubMed ID: 20358419 [Abstract] [Full Text] [Related]
40. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data]. Ewald N, Toepler M, Akinci A, Kloer HU, Bretzel RG, Hardt PD. Z Gastroenterol; 2005 Dec 15; 43(12):1313-7. PubMed ID: 16315127 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]